{"entity": "researcher", "timestamp": "2026-08-20T20:43:17.925Z", "family": "Angori", "given": "Silvia", "initials": "S", "orcid": "0000-0002-5823-3670", "affiliations": ["Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/d7b19bdfb2fb4895b7cc2674966c26d8.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/d7b19bdfb2fb4895b7cc2674966c26d8"}}, "publications": [{"entity": "publication", "iuid": "7549eaddf1bc4f51b2758ea9d5280347", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/7549eaddf1bc4f51b2758ea9d5280347.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/7549eaddf1bc4f51b2758ea9d5280347"}}, "title": "Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma.", "authors": [{"family": "Angori", "given": "Silvia", "initials": "S", "orcid": "0000-0002-5823-3670", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d7b19bdfb2fb4895b7cc2674966c26d8.json"}}, {"family": "Lakshminarayanan", "given": "Harini", "initials": "H"}, {"family": "Banaei-Esfahani", "given": "Amir", "initials": "A"}, {"family": "M\u00fchlbauer", "given": "Katharina", "initials": "K"}, {"family": "Bolck", "given": "Hella Anna", "initials": "HA", "orcid": "0000-0001-5157-0490", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/37523ade9b314620a766c4efce7b2c56.json"}}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Pieti\u00e4inen", "given": "Vilja", "initials": "V"}, {"family": "Schraml", "given": "Peter", "initials": "P"}, {"family": "Moch", "given": "Holger", "initials": "H"}], "type": "journal article", "published": "2025-04-01", "journal": {"title": "Int. J. Cancer", "issn": "1097-0215", "volume": "156", "issue": "7", "pages": "1457-1469", "issn-l": "0020-7136"}, "abstract": "Papillary renal cell carcinoma (pRCC) is the second most frequent renal cancer subtype but has no indicated targeted treatments. MET inhibition may be a treatment for MET-driven pRCC, but there is a large group of non-MET-driven pRCC without targeted therapy. Activation of NRF2-ARE pathway has been suggested to be involved in pRCC. To study the relevance of the NRF2-ARE pathway, we characterized 60 pRCCs by copy number analysis and Whole Exome Sequencing. Because stabilisation of NRF2 results in enhanced expression of NQO1, a reductase that prevents production of reactive oxygen species, protein expression of NQO1 was analysed by immunohistochemistry (IHC) from tissue microarrays (TMAs) and by enzymatic activity assay. Finally, patient-derived pRCC cells (PDCs) were applied for drug profiling with 18 NRF2-ARE pathway inhibitors. We identified MET mutations in 5%, and mutations in four genes of NRF2-ARE pathway (NFE2L2, KEAP1, CUL3 and BACH1) in 10% of 60 pRCC samples. IHC analysis of TMAs of 638 renal cancers showed the correlation of the expression of NQO1 with poor survival outcome (p < .001) and high tumour grade (p < .001) and stage (p < .001) in pRCC. NQO1 mRNA, protein levels and enzymatic activity were increased in 56% of matched pRCC tissue samples and patient-derived cells (PDCs, n = 9). Drug screening revealed that Brusatol and Convallatoxin are potential novel drugs for pRCC. Inhibition of NRF2 represents a novel therapeutic approach for MET-independent pRCC patients.", "doi": "10.1002/ijc.35311", "pmid": "39707614", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11789458"}], "notes": [], "created": "2026-08-20T06:33:40.660Z", "modified": "2026-08-20T06:33:40.788Z"}]}